» Articles » PMID: 29323558

Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States

Overview
Date 2018 Jan 12
PMID 29323558
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Preexposure prophylaxis (PrEP) is a highly effective HIV prevention method; however, it is underutilized among women who are at risk for acquisition of HIV. Women comprise one in five HIV diagnoses in the United States, and significant racial disparities in new HIV diagnoses persist. The rate of new HIV diagnoses among black and African American women in 2015 was 16 times greater than that of white women. These disparities highlight the importance of HIV prevention strategies for women, including the use of PrEP. PrEP is the first highly effective HIV prevention method available to women that is entirely within their control. However, because so few women who may benefit from PrEP are aware of it, few women's healthcare providers offer PrEP to their patients, PrEP has not yet achieved its potential to reduce HIV infections in women. This article describes individual and systemic barriers for women related to the uptake of PrEP services; explains how providers can identify women at risk for HIV; reviews how to provide PrEP to women; and outlines client-centered models for HIV prevention services. Better access to culturally acceptable and affordable medical and social services may offer support to women for consistent and ongoing use of PrEP. This discussion may be used to inform HIV prevention activities for women and guide interventions to decrease racial/ethnic disparities in rates of HIV infection among US women.

Citing Articles

Assessing Non-Oral PrEP Alternatives Among Young Black Women in the Southern USA.

Denson D, Tesfaye C, Glusberg D, Schoua-Glusberg A, Betley V, Gale B J Racial Ethn Health Disparities. 2025; .

PMID: 39760837 DOI: 10.1007/s40615-024-02263-y.


Protocol: the American Women: Assessing Risk Epidemiologically (AWARE) cohort study.

Schnall R, Kempf M, Phillips 2nd G, Dionne J, Wingood G, Long D BMC Public Health. 2024; 24(1):3422.

PMID: 39695485 PMC: 11653693. DOI: 10.1186/s12889-024-20810-4.


Mapping Implementation Strategies to Address Barriers to Pre-Exposure Prophylaxis Use Among Women Through POWER Up (Pre-Exposure Prophylaxis Optimization Among Women to Enhance Retention and Uptake): Content Analysis.

Johnson A, Devlin S, Pyra M, Etshokin E, Ducheny K, Friedman E JMIR Form Res. 2024; 8():e59800.

PMID: 39546769 PMC: 11607547. DOI: 10.2196/59800.


Increasing Engagement in Human Immunodeficiency Virus Prevention Among Cisgender Women in New York City With Sexual Health Self-Testing Kits: A MaxDiff Analysis.

Goldberg A, Price D, Phi A, Ma M, Edelstein Z, Golub S Sex Transm Dis. 2024; 52(3):181-187.

PMID: 39508465 PMC: 11794027. DOI: 10.1097/OLQ.0000000000002096.


An Examination of Perceptions among Black Women on Their Awareness of and Access to Pre-Exposure Prophylaxis (PrEP).

Hill M, Sapp S, McCants S, Campbell J, Taylor A, Stockman J Int J Environ Res Public Health. 2024; 21(8).

PMID: 39200693 PMC: 11354061. DOI: 10.3390/ijerph21081084.


References
1.
McKay T, Mutchler M . The effect of partner sex: nondisclosure of HIV status to male and female partners among men who have sex with men and women (MSMW). AIDS Behav. 2010; 15(6):1140-52. PMC: 3127004. DOI: 10.1007/s10461-010-9851-4. View

2.
Smith D, Van Handel M, Wolitski R, Stryker J, Hall H, Prejean J . Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015. J Miss State Med Assoc. 2016; 56(12):364-71. View

3.
Pouget E, Kershaw T, Niccolai L, Ickovics J, Blankenship K . Associations of sex ratios and male incarceration rates with multiple opposite-sex partners: potential social determinants of HIV/STI transmission. Public Health Rep. 2010; 125 Suppl 4:70-80. PMC: 2882977. DOI: 10.1177/00333549101250S411. View

4.
Cottrell M, Yang K, Prince H, Sykes C, White N, Malone S . A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. J Infect Dis. 2016; 214(1):55-64. PMC: 4907409. DOI: 10.1093/infdis/jiw077. View

5.
Campbell J, Herbst J, Koppenhaver R, Smith D . Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med. 2012; 44(1 Suppl 2):S63-9. DOI: 10.1016/j.amepre.2012.09.045. View